Neuberger Berman Group
VNDA icon

Neuberger Berman Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Neuberger Berman Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-45,500
Closed -$1.04M – 1659
2018
Q3 		$1.04M Buy
45,500
+15,500
+52% +$316K ﹤0.01% 1179
2018
Q2 		$572K Buy
+30,000
New +$502K ﹤0.01% 1366

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Neuberger Berman Group's VNDA Position: Q4 2018 in Review

Neuberger Berman Group sold out of Vanda Pharmaceuticals (VNDA) in Q4 2018, closing a stake of 45,500 shares — an estimated $1.04M sold.

Neuberger Berman Group first reported a position in VNDA in Q2 2018 and held it in 2 quarters. The position peaked at $1.04M in Q3 2018. 186 funds tracked by Wall St. Rank hold VNDA as of Q4 2018.

  • Neuberger Berman Group reported no remaining Vanda Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Neuberger Berman Group sold 45,500 Vanda Pharmaceuticals shares in Q4 2018, an estimated $1.04M.
  • Neuberger Berman Group first reported a position in Vanda Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Neuberger Berman Group's Vanda Pharmaceuticals position peaked at $1.04M in Q3 2018.
  • 186 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2018.

Based on Neuberger Berman Group's 13F filing for Q4 2018, filed 12 Feb 2019.